Evaluation of the efficacy and safety of selumetinib in neurofibromatosis

As a rare genetic disease, the treatment of neurofibromatosis has always been a difficult problem in the medical field. Especially for patients who cannot tolerate surgery or radiotherapy, it is particularly urgent to find effective treatments. In recent years, selumetinib (Selumetinib), as a new type of targeted therapy, has brought new hope for the treatment of neurofibroma. This article will start from clinical trial data to comprehensively analyze the efficacy and safety of selumetinib in the treatment of neurofibromatosis.

1. Therapeutic mechanism of selumetinib

Selumetinib, as a MEK inhibitor, inhibits the proliferation and metastasis of tumor cells by precisely blocking the MEK signaling pathway. This mechanism of action targets the key molecule MEK in the RAS-MAPK signaling pathway. By interfering with its normal signaling process, it achieves the purpose of inhibiting the abnormal proliferation of neurofibroma cells.

2. Clinical trial data and efficacy analysis

InSPRINT(NCT The efficacy of selumetinib was studied in 01362803, an open-label, multicenter, single-arm trial sponsored by the National Cancer Institute (NCI). Treat pediatric patients with NF1 and measurable PN that cannot be surgically removed without significant risk of morbidity. Patients in the efficacy population (N=50) were also required to have at least one significant morbidity rate associated with the target PN. Disfigurement, motor dysfunction, pain, airway dysfunction, visual impairment, and bladder/intestinal dysfunction occur in ≥20%of patients. Patients received oral selumetinib at 25 mg/m twice daily until disease progression or unacceptable toxicity.

The primary efficacy outcome measure isNCIassessed overall response rate (ORR), defined as3-6MRI) within an>months of ≥20%. The effective rate was 66% (n = 33; 95%confidence interval :51.79). All patients had a partial response, and 82% of responders continued to respond for at least 12 months. An independent centralized review of ORR using the same response criteria showed an ORR of 44% (95% CI: 30, 59). Primary safety data were obtained from 74 pediatric patients with NF1 and PN who received selumetinib during SPRINT. The most common adverse reactions (≥40% of patients) were vomiting, rash, abdominal pain, diarrhea, nausea, dry skin, fatigue, musculoskeletal pain, pyrexia, acne, stomatitis, headache, paronychia, and pruritus.

3. Adverse reactions and safety assessment

Although selumetinib has shown remarkable efficacy in the treatment of neurofibromatosis, we also need to pay attention to its possible adverse reactions and safety issues. Some common adverse reactions observed in clinical trials include skin reactions, gastrointestinal discomfort, and cardiovascular-related toxicities. Therefore, when treating with selumetinib, doctors need to closely monitor the patient's physical condition and detect and deal with these adverse reactions in a timely manner to ensure the safety and effectiveness of the treatment. At the same time, patients also need to actively cooperate with doctors’ treatment suggestions and conduct regular examinations and follow-up visits in order to adjust treatment plans in a timely manner and protect their own health and safety.

In summary, selumetinib, as a new type of targeted therapy, has demonstrated significant efficacy and good safety in the treatment of neurofibromatosis. By precisely blockingMEKSignaling pathways to inhibit the proliferation and metastasis of tumor cells provide new treatment options for patients with neurofibromatosis and bring hope of improving prognosis and quality of life. However, it is still necessary to monitor adverse reactions during use and take corresponding measures in a timely manner to ensure the health and safety of patients. In the future, with the deepening of research and the advancement of technology, we believe that more effective and safe treatments will be available to bring better therapeutic effects and quality of life to patients with neurofibromatosis.